There has been a lot of information shared recently about Medicare and obesity medications (GLP-1s). Here’s what we know right now from the Centers for Medicare & Medicaid Services (CMS).
n
The Medicare GLP-1 Bridge is a temporary program designed to help people with Medicare access GLP-1 medications used as part of obesity care. Because Medicare does not typically cover these medications, the Bridge creates a separate pathway to make them available.
n
CMS has announced that the Medicare GLP-1 Bridge will begin on July 1, 2026, and continue through December 31, 2027. This means eligible Medicare beneficiaries will have about a year and a half to access GLP-1 medications outside of standard Part D insurance coverage.
n
At the same time, CMS has delayed part of a longer-term program called the BALANCE Model. This program is still being evaluated as a future option for broader Medicare coverage of these medications.
n
In the short term, the Bridge program is an important step forward. It allows people to access treatment while also helping CMS better understand how these medications are used, their impact on health, and what long-term coverage could look like.
n
It’s also important to know that this program will work differently than typical Medicare prescription coverage. Details about enrollment and the approval process are still being finalized, and more information is expected soon.
n
The Obesity Action Coalition (OAC) will continue working with CMS and other advocacy partners to share more information about the program as details become available in the coming months.
n
This update matters because access to obesity care continues to be a challenge for many people. Expanding access to safe, effective treatment options remains a key priority.
n
Bottom line: Progress is happening. July 1, 2026, is an important date, and this program represents a meaningful step toward improving access to obesity care for people with Medicare.
n
Together, we can continue to advocate for better access to comprehensive, science-based obesity care. Stay tuned for updates.
n
